New study: Stargardt Disease Therapeutics and In-depth Research on Market Size, Share, Trends, Emerging Growth

Stargardt Disease Therapeutics Market is expected to have a highly positive outlook for the next five years 2018-2026 according to a recently released Stargardt Disease Therapeutics Market research report. The report has been added in his large database by Coherent Market Insights. This report is a guide which covers key strategic developments of the market including acquisitions & mergers, new technology launch, agreements, partnerships, collaborations & joint ventures, research & development, technology and regional expansion of major participants involved in the market on the global and regional basis.

Stargardt disease is an inherited juvenile macular degeneration that causes vision loss. The signs and symptoms of the disease typically appear in late childhood or early adulthood and worsen with time. The most common cause of the disease is mutations in the ABCA4 gene. People suffering from stargardt disease might notice grey or black color in the middle of eye, or eyes may be more sensitive to bright light. Others may even have symptoms of color blindness. The prevalence for the disease is low, reported at around 1 in 8,000-10,000 people globally, as stated by National Eye Institute in April 2015. Hence, the disease falls into rare disease category. Till date, there is no treatment available, though there are multiple therapies in pipeline.

Download PDF Brochure@ https://www.coherentmarketinsights.com/insight/request-pdf/1314

Robust pipeline for each treatment type that may get regulatory approval over the forecast period is expected to boost the growth of stargardt disease therapeutics market

Treatment options for Stargardt disease include drug, gene therapy and stem cell therapy. There are products in each of these category currently in clinical trials. For instance, Nightstar Therapeutics expanded its pipeline with gene therapy program for Stargardt Disease treatment in November 2017. In drug category, certain companies have received orphan drug designation from U.S. FDA. For instance, in January 2017, Acucela Inc. received orphan drug designation for its leading product emixustat for the treatment of stargardt disease. In October 2017, Lin BioScience also received orphan n drug designation for its leading product LBS-008 for the treatment of Stargardt Disease. Furthermore, companies such as Astellas Pharma Inc. is working on stem cell therapy for Stargardt disease. With the approval of some of the therapy that are currently in pipeline, the global stargardt disease therapeutics market is expected to witness rapid growth over the forecast period.

Stargardt Disease Therapeutics Market Taxonomy:

By Treatment Type:

Drugs
Gene Therapy
Stem Cell Therapy
By Stages of Development:

Children
Adult
North America is expected to hold a dominant position in the global stargardt disease therapeutics market

Acucela Inc. and Lin Bioscience have received orphan drug designation for their respective products, and are headquartered in U.S. Other companies such as Astellas Pharma Inc, Copernicus Therapeutics Inc. and Sanofi S.A. are either U.S.-based or have considerable presence in U.S. This positions North America as a major market for stargardt disease. Europe is expected to hold second position in stargardt disease therapeutics market as companies like Nightstar therapeutics has shown interest in developing treatment for stargardt disease. In Asia Pacific region, Japan is home to companies such as Astellas Pharma Inc. Also, major Japan-based pharmaceutical companies are working with small-size Company operating in this area. For instance, Otsuka Pharmaceutical Co., Ltd., a Japan-based company, has continued its collaboration agreement with Acucela Inc., a clinical stage company working on stargardt disease, since 2008.

Key players operating in stargardt disease therapeutics market include Nemus Bioscience Inc., Acucela Inc., Katairo, Ocata Therapeutics Inc., Sanofi, Alkeus Pharmaceuticals Inc., Astellas Pharma Inc., Copernicus Therapeutics Inc., Grupo Ferrer Internacional SA, Iris Pharma, Ophthotech Corp, ProQR Therapeutics NV.

Request for Customization@ https://www.coherentmarketinsights.com/insight/request-customization/1314

Important Features that are under offering & key highlights of the report:

1) What all companies are currently profiled in the report?
The report Contain the Major Key Players currently profiled in this market.
** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

2) Can we add or profiled new company as per our need?

Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by research team depending upon the difficulty of survey.
** Data availability will be confirmed by research in case of privately held company. Upto 3 players can be added at no added cost.
3) What all regional segmentation covered? Can specific country of interest be added?
Currently, research report gives special attention and focus on following regions:
North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc), South America (Brazil, Argentina etc) & Middle East & Africa (Saudi Arabia, South Africa etc)
** One country of specific interest can be included at no added cost. For inclusion of more regional segment quote may vary.

4) Can inclusion of additional Segmentation / Market breakdown is possible?

Yes, inclusion of additional segmentation / Market breakdown is possible subject to data availability and difficulty of survey. However a detailed requirement needs to be shared with our research before giving final confirmation to client.
** Depending upon the requirement the deliverable time and quote will vary.

To comprehend 2018-2026 Stargardt Disease Therapeutics Market dynamics in the world mainly, the worldwide 2018-2026 Stargardt Disease Therapeutics Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.